Livongo Health Secures $20M in Series B Funding
Summary
Backers included Kleiner Perkins Caufield & Byers, DFJ and previous investor General Catalyst.The company intends to use the funds to further develop its chronic disease management ecosystem and accelerate the adoption of its digital diabetes management program, Livongo for Diabetes™, among self-insured employers, healthcare providers and payers.In conjunction with the funding, Dr. Beth Seidenberg, General Partner at KPCB, and Emily Melton, Partner at DFJ, will be joining Livongo Health’s Board of Directors.Launched in September 2014 by Glen Tullman, Chief Executive Officer, Livongo Health provides people with a digital platform to manage chronic conditions, beginning with diabetes.Each user receives a blood glucose smartmeter, which captures a user’s biometric data and uploads it to a cloud-based inference engine where historical data, clinical rules and predictive modeling are used to convert it into information and support.